Market capitalization | $1.31m |
Enterprise Value | $0.00 |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.00 |
EV/Sales (TTM) EV/Sales | 0.00 |
P/S ratio (TTM) P/S ratio | 0.15 |
P/B ratio (TTM) P/B ratio | 0.69 |
Revenue growth (TTM) Revenue growth | 3.66% |
Revenue (TTM) Revenue | $8.97m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Nuwellis Inc forecast:
2 Analysts have issued a Nuwellis Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8.97 8.97 |
4%
4%
|
|
Gross Profit | 5.71 5.71 |
16%
16%
|
|
EBITDA | -12 -12 |
35%
35%
|
EBIT (Operating Income) EBIT | -12 -12 |
34%
34%
|
Net Profit | -15 -15 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Head office | United States |
CEO | Nestor Jaramillo |
Employees | 59 |
Founded | 1999 |
Website | www.nuwellis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.